Elvucitabine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Elvucitabine
Elvucitabine.png
Systematic (IUPAC) name
4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
Clinical data
Legal status
?
Identifiers
CAS number 181785-84-2 YesY
ATC code None
PubChem CID 469717
UNII M09BUF90C0 YesY
ChEMBL CHEMBL38700 N
NIAID ChemDB 060327
Chemical data
Formula C9H10FN3O3 
Mol. mass 227.19 g/mol
 N (what is this?)  (verify)

Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV.

Currently, it is in Phase II clinical trials.[1]

References[edit]

  1. ^ "Elvucitabine". AIDSmeds.com. November 5, 2007. Retrieved March 21, 2008.